2.4. Pharmacological Inhibition of Ezrin by NSC305787 Increases the Response of the Resistant RKO Colon Cancer Cells to Vemurafenib and Concurs with a Downregulation of CD44 Expression and Inhibition of AKT/c-Myc Signaling. The gene discussed is MYC; the disease is colonic neoplasm.